Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Analysis: $1.57 Billion by 2029 With a CAGR of 4.6%

Stay informed on tariff shifts, macro trends, and global economic changes-use code ONLINE30 to enjoy 30% off our global market reports.

Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Value Projection: How Much Will the Market Size by 2025?
The market size for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer has seen a consistent growth in the past few years. The market value which stands at $1.25 billion in 2024 is expected to see an increase to $1.31 billion in 2025, with a compound annual growth rate (CAGR) of 4.8%. The upward trend in the previous years is attributed to factors such as the increasing use of companion diagnostics, heightened awareness about HER2 biomarkers among oncologists, an increased emphasis on personalized cancer treatments, growing interest in antibody-drug conjugates, and broader reimbursement scenarios for targeted therapies.

What Will Be the Market Growth Forecat for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer in 2029?
In the coming years, the market size for human epidermal growth factor receptor 2 (HER2)-positive gastric cancer is anticipated to experience consistent growth, eventually reaching $1.57 billion in 2029 with a compound annual growth rate (CAGR) of 4.6%. This growth for the forecasted period can be ascribed to factors such as the growing prevalence of molecular diagnosis laboratories, increased awareness campaigns on gastric cancer screening, escalating utilization of Next-generation sequencing (NGS), the burgeoning demand for outpatient cancer care services, and more global regulatory approvals of HER2 drugs. Key trends for the forecast period include enhancing treatment sequences, the application of nanotechnology in drug delivery, the use of artificial intelligence in HER2 diagnostics, improving antibody-dependent cellular cytotoxicity, and progress in immunotherapy combinations.

Explore The Complete Report Now:
https://www.thebusinessresearchcompany.com/report/human-epidermal-growth-factor-receptor-2-her2-positive-gastric-cancer-global-market-report

What Are the Core Competitive Drivers in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Industry?
The growth of the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market is anticipated to be fueled by the growing implementation of targeted cancer therapy. This treatment method, also known as personalized medicine, specifically uses unique drugs or substances to inhibit cancer growth by focusing on specific molecules implicated in tumor formation. The increased use of targeted therapy can be largely attributed to progress in genetic profiling, as this allows for more accurate treatments tailored to a patient's unique tumor characteristics, resulting in enhanced effectiveness and reduced side-effects. In the case of HER2-positive gastric cancer, targeted therapy operates by directly attacking the HER2 protein, which is overproduced in these tumors, thus slowing the progression of the disease and improving patient outcomes. For instance, as reported by the Personalized Medicine Coalition, a professional membership organization based in the US, in February 2024, the Food and Drug Administration (FDA) approved 16 new personalized medicines, including 7 cancer drugs and three drugs for various other diseases and conditions in 2023, marking an increase from 6 in 2022. As such, the expanding use of targeted cancer therapy is a major driver in the growth of the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market.

Get Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25787&type=smp

Which Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market Segment Is Projected to See the Fastest Growth?
The human epidermal growth factor receptor 2 (her2)-positive gastric cancer market covered in this report is segmented -

1) By Therapy: Chemotherapy, Immunotherapy, Radiation Therapy, Targeted Therapy
2) By Stage: Stage I, Stage II, Stage III, Stage IV
3) By End-User: Ambulatory Surgery Centers, Hospitals And Specialty Clinics, Other End-Users

Subsegments:
1) By Chemotherapy: Fluoropyrimidines, Platinum-Based Agents, Taxanes, Irinotecan, Anthracyclines
2) By Immunotherapy: Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cancer Vaccines, Cytokine-Based Therapies
3) By Radiation Therapy: External Beam Radiation Therapy, Intensity-Modulated Radiation Therapy, Stereotactic Body Radiation Therapy, 3D Conformal Radiation Therapy
4) By Targeted Therapy: HER2-Targeted Therapies, Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, mTOR Inhibitors, PI3K/AKT/mTOR Pathway Inhibitors

Which Trends Are Opening New Opportunities in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?
A focus on attaining approvals for innovative therapies like advanced immunotherapy-enhanced combination regimens, including the incorporation of immune checkpoint inhibitors with targeted therapy and chemotherapy, is exhibited by the key players in the HER2-positive gastric cancer segment. This advanced approach works by using the patient's immune system to inhibit programmed death (PD)-1 or programmed death (PD)-L1 interactions, targeting HER2 receptors, and employing chemotherapeutic agents to increase anti-tumor activity and enhance survival rates. For instance, in March 2025, FDA approval was granted to the US-based biopharmaceutical company, Merck & Co., Inc., for their drug, pembrolizumab (Keytruda). The drug, in combination with trastuzumab and chemotherapy, serves as a first-line treatment for adults diagnosed with HER2-positive inoperable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma, whose tumors express programmed death (PD)-L1. This newly approved combination therapy has shown significant enhancement in median progression-free survival and overall survival when compared to standard treatments. With an overall response rate of 73% and increased median duration of response, this treatment sets a new standard for managing advanced HER2-positive gastric cancers.

Customize Your Insights And Get The Full Report Here:
https://www.thebusinessresearchcompany.com/customise?id=25787&type=smp

Who Are the Leaders in the Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Market?
Major companies operating in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market are Pfizer Inc., Roche Holding AG, Merck & Co Inc., Bayer Aktiengesellschaft, Eli Lilly and Company, Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, Amgen Inc., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Genentech Inc., Ono Pharmaceutical Co Ltd., Shanghai Henlius Biotech Inc., MacroGenics Inc., Hutchison Medipharma Limited , ALX Oncology Holdings Inc., Taiho Pharmaceutical Co Ltd., Ambrx Biopharma Inc., LintonPharm Co Ltd.

Which Regional Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Gastric Cancer Markets Offer the Greatest Growth Potential?
North America was the largest region in the human epidermal growth factor receptor 2 (HER2)-positive gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human epidermal growth factor receptor 2 (her2)-positive gastric cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out to Us Speak With Our Expert: Saumya Sahay
Americas +1 310-496-7795,
Asia +44 7882 955267 & +91 8897263534,
Europe +44 7882 955267
Email: saumyas@tbrc.info
The Business Research Company - www.thebusinessresearchcompany.com
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.